Eugit Therapeutics

Enabling Tissue Targeting of Therapies

Eugit Therapeutics operates in healthcare based in San Francisco, CA, USA; South San Francisco, CA, USA.

Profile

Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years.

Cofounded by George Church (Harvard) and funded by Y Combinator (S22).

Eugit Therapeutics is positioned in healthcare, a segment that rewards a clear, focused offering.

The business is associated with San Francisco, CA, USA; South San Francisco, CA, USA.

The company is listed at the Summer 2022 stage of development.

The company reports a headcount in the 2 range.

Website: www.eugittx.com